Edition:
United Kingdom

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

40.05USD
9:00pm BST
Change (% chg)

$1.06 (+2.72%)
Prev Close
$38.99
Open
$39.06
Day's High
$40.11
Day's Low
$38.98
Volume
88,268
Avg. Vol
120,404
52-wk High
$46.12
52-wk Low
$24.32

Latest Key Developments (Source: Significant Developments)

Audentes Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted By The FDA To AT132
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED BY THE FDA TO AT132 FOR THE TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY.AUDENTES THERAPEUTICS - PLAN TO MEET WITH FDA TO GAIN ALIGNMENT ON AT132 DEVELOPMENT PLAN.  Full Article

Audentes Therapeutics Reports Qtrly Loss Per Share $0.85
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Audentes Therapeutics Inc ::AUDENTES THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON ASPIRO, THE PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.AUDENTES THERAPEUTICS - NO SERIOUS ADVERSE EVENTS IN PATIENTS SINCE LAST UPDATE PROVIDED AT ASGCT IN MAY 2018 IN PHASE 1/2 CLINICAL TRIAL OF AT132.AUDENTES THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.85.  Full Article

Audentes Announces Data From First Dose Cohort Of ASPIRO
Wednesday, 16 May 2018 

May 16 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.PATIENT 1 HAS ACHIEVED VENTILATOR INDEPENDENCE AND ORAL FEEDING.SIGNIFICANT IMPROVEMENTS IN NEUROMUSCULAR AND RESPIRATORY FUNCTION AT 24-WEEK TIMEPOINT.HAVE BEEN TOTAL OF 24 ADVERSE EVENTS REPORTED IN ASPIRO, SIX OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS.THERE HAVE BEEN AN ADDITIONAL 11 NON-SERIOUS AES IN ASPIRO, ALL DETERMINED TO BE NOT TREATMENT-RELATED.  Full Article

Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 2018.TOTAL 6 ADVERSE EVENTS (AES) REPORTED IN ASPIRO, 2 OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS (SAES).‍OF FOUR NON-SERIOUS ADVERSE EVENTS, TWO HAVE BEEN DETERMINED TO BE PROBABLY OR POSSIBLY TREATMENT-RELATED​.‍AUDENTES PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 OF 2018​.  Full Article

Audentes Therapeutics Q3 ‍loss per share $ 0.88​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update.Audentes Therapeutics inc qtrly ‍loss per share $ 0.88​.  Full Article

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY